T/FIF Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BulbaMan who wrote (995)	6/21/1999 9:32:00 AM
From: scaram(o)uche	Read Replies (3) of 1073

Bulba: Haven't looked at them closely since Iterex Pharm. modified the magainin molecule itself to enhance anti-bacterial activity. Iterex subsequently became Houghten Pharm which subsequently became Trega. So, it's been awhile. Is there a pulse after the beating at the advisory committee meeting? I don't agree that Trovan's problems will have any effect on MAGN. I haven't looked closely at the anti-angiogenisis stuff. Seemed likely to be low "specific activity" stuff compared to SUGN, OSIP and the like, but I'm interested in concurrent use of anti-angio molecules with differing mechs/toxicities. I think that Mike has been poking around it? Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next